Utah tests AI-issued acne prescriptions, with human review tied to each stage
Nolla’s Utah pilot can move from physician approval before every prescription to review afterward, but only within a narrow acne formulary and with written state approval.
Nolla announced its Utah launch on October 5.
A signed state agreement permits first prescriptions and renewals for topical acne treatment in eligible Utah adults, under a staged oversight plan. The significance is where clinical responsibility sits as software gains permission to act. [1][2]
Initially, two independent Utah-licensed physicians must review every prescription before it is issued. That stage lasts at least four weeks and covers at least 100 patients. The next stage permits issue first and review afterward: every case, at least weekly, for at least eight weeks and 500 patients cumulatively. [1]
Later oversight samples at least 10% of enrollment monthly, while reviewing every adverse-event or escalated case. Each advancement requires written state approval. Those conditions describe the intended safeguards; they do not demonstrate that autonomous prescribing has improved access or patient outcomes. [1]
The boundary is narrow: adults with mild-to-moderate acne, a specified topical formulary, and exclusions including pregnancy and severe acne. Oral medicines and isotretinoin are outside the pilot. The agreement explicitly disclaims state endorsement of the technology. [1]
Sources & details 3 sources
Discuss in your voice app
Take the reporting, visual explanations and original sources into a conversation. Copy the brief, paste it into your preferred assistant, then start its voice mode.
Paste the brief into your voice app to discuss this reporting.Revised 9 October 2026. Copy edited 9 October to remove commentary about graphic design; reported claims, qualifications and source dates preserved.
Reporting sources
- Utah Department of Commerce · Signed Nolla agreement
Original 50-page PDF downloaded and read after collection. Pages 1–2, 11–15, 30–33 and 40–41 establish scope, stage minima, review cadence, exclusions and non-endorsement.
- Nolla Health · October 5 launch statement
Counterparty account confirms launch and staged review. Its “up to 500” wording differs from the signed protocol’s cumulative minimum; the contract controls here.
- Bloomberg / Los Angeles Times · Independent reporting
Independent reporting corroborates the state’s narrow prescribing exemption. Its simplified stage counts are not used as the governing requirements.
Images & figures
The signed agreement changes when review occurs. Stage 1 requires two independent physician reviews before issue; stage 2 reviews every case at least weekly afterward; stage 3 samples at least 10% of enrollment monthly, plus every adverse event or escalation. These are required safeguards, not verified outcome data. Stage 3 also specifies at least 750 cumulative patients.
Euangelion · original explanatory graphic · Source · Usage terms